Metastatic Breast Cancer Overview
Metastatic Breast Cancer also called stage IV - is breast cancer that has spread to another part of the body, most commonly the bones, lungs, brain, or liver.
“Metastatic Breast Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.
The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. Metastatic Breast Cancer Key players such as - Menarini Group, Phoenix Molecular Designs, Dantari, Inc., AstraZeneca, Orion Pharma, Tyme, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Miracogen Inc., Syncore Biotechnology, Byondis, RemeGen, and others, are developing therapies for the Metastatic Breast Cancer treatment
- Metastatic Breast Cancer Emerging therapies such as - MEN1611, PMD-026, DAN-222, AZD 8205, ODM-209, SM-88, KN026, MRG002, SB 05, Trastuzumab duocarmazine, Disitamab (RC48)Vedotin, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
- In September 2021, Seagen Inc. announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC
- In September 2020, RemeGen Co., Ltd. initiated a randomized, controlled, multicenter Phase III clinical study evaluating the efficacy and safety of RC48-ADC for the treatment of Locally Advanced or Metastatic Breast Cancer with low expression of HER2
Route of Administration
Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Metastatic Breast Cancer Pipeline Therapeutics Assessment
- Metastatic Breast Cancer Assessment by Product Type
- Metastatic Breast Cancer By Stage and Product Type
- Metastatic Breast Cancer Assessment by Route of Administration
- Metastatic Breast Cancer By Stage and Route of Administration
- Metastatic Breast Cancer Assessment by Molecule Type
- Metastatic Breast Cancer by Stage and Molecule Type
DelveInsight's Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Breast Cancer are - RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
- MEN1611: Menarini Group
- PMD-026: Phoenix Molecular Designs
- DAN-222: Dantari, Inc.
- AZD 8205: AstraZeneca
- ODM-209: Orion Pharma
- SM-88: Tyme, Inc.
- KN026: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- MRG002: Shanghai Miracogen Inc.
- SB 05: Syncore Biotechnology
- Trastuzumab duocarmazine: Byondis
- Disitamab (RC48) Vedotin: RemeGen
Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment
Metastatic Breast Cancer Pipeline Analysis:
The Metastatic Breast Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
- Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies
Metastatic Breast Cancer Pipeline Market Drivers
- Increasing prevalence of breast cancer
- Increasing investments in R&D
- Launch of several diagnostic and screening programs
Metastatic Breast Cancer Pipeline Market Barriers
- High cost associated with the treatment
- Several side effects associated with the use of breast cancer therapeutics
Scope of Metastatic Breast Cancer Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Breast Cancer Companies: Menarini Group, Phoenix Molecular Designs, Dantari, Inc., AstraZeneca, Orion Pharma, Tyme, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Miracogen Inc., Syncore Biotechnology, Byondis, RemeGen, and others
- Key Metastatic Breast Cancer Therapies: MEN1611, PMD-026, DAN-222, AZD 8205, ODM-209, SM-88, KN026, MRG002, SB 05, Trastuzumab duocarmazine, Disitamab (RC48)Vedotin, and others
- Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
- Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers
Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
| 1 | Metastatic Breast Cancer Report Introduction |
| 2 | Metastatic Breast Cancer Executive Summary |
| 3 | Metastatic Breast Cancer Overview |
| 4 | Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment |
| 5 | Metastatic Breast Cancer Pipeline Therapeutics |
| 6 | Metastatic Breast Cancer Late Stage Products (Phase II/III) |
| 7 | Metastatic Breast Cancer Mid Stage Products (Phase II) |
| 8 | Metastatic Breast Cancer Early Stage Products (Phase I) |
| 9 | Metastatic Breast Cancer Preclinical Stage Products |
| 10 | Metastatic Breast Cancer Therapeutics Assessment |
| 11 | Metastatic Breast Cancer Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Metastatic Breast Cancer Key Companies |
| 14 | Metastatic Breast Cancer Key Products |
| 15 | Metastatic Breast Cancer Unmet Needs |
| 16 | Metastatic Breast Cancer Market Drivers and Barriers |
| 17 | Metastatic Breast Cancer Future Perspectives and Conclusion |
| 18 | Metastatic Breast Cancer Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
